Cancer-fighting t cells burn out. Scientists may have found a fix
Researchers at Memorial Sloan Kettering have identified the MEK signaling molecule as a primary driver of T cell exhaustion in cancer immunotherapy. By blocking this molecule, scientists believe they can prevent T cells from burning out, potentially extending the effectiveness of existing cancer treatments.
Why it matters
This discovery could significantly improve the success rates of cancer immunotherapy, turning temporary treatments into more durable solutions for patients.
Cancer immunotherapy can unleash T cells, the immune system's specialized cancer killers, against tumors. But there is a major limitation: These cells can become worn down before the cancer is eliminated. This condition, known as T cell exhaustion, leaves the cells unable to maintain a strong attack or keep tumor growth under control.
That problem has been particularly important for checkpoint inhibitors, immunotherapy drugs designed to remove biological restraints that normally limit T cell activity.
"A tragic part of T cell exhaustion is that the immunotherapy seems to be working for patients, and then it fades," says Santosha Vardhana, MD, PhD, a physician-scientist at Memorial Sloan Kettering Cancer Center (MSK) who treats people with lymphoma. "Many of them experience a brief wisp of promise only to have it taken away."
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in